VG-203

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameVG-203
Drug Alias NameVG-203VG2062VG-2062
ClassificationCell and gene therapy > Gene therapyBiologics > Oncolytic virus
Mechanisms of ActionInterleukin-12 stimulantsInterleukin-15 stimulantsInterleukin-15 receptor subunit alpha stimulants +[5] 
TargetsInterleukin-15 receptor subunit alphaInterleukin-15Interleukin-12
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesViroGin Biotech LtdShanghai Funuojian Biotechnology Co LtdVirogin Biotech (Shenzhen) Ltd +[4] 
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesVirogin Biotech (Shenzhen) LtdFenojian Biotechnology (Nantong) Co LtdShanghai Funuojian Biotechnology Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursOvarian NeoplasmsBreast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A